Pancreatic Cancer Research

ResearcherFudan UniversityNo recent work listed

Hexige Saiyin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2993-6817; OpenAlex author ID A5088677379. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers

Papers 9

  1. IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41401-022-01035-w↗
  2. Construction of a pancreatic cancer nerve invasion system using brain and pancreatic cancer organoids. Co-author DOI 10.1177/20417314221147113↗
  3. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  4. Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. First author DOI 10.1097/mpa.0000000000001023↗
  5. LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer. First author DOI 10.1371/journal.pone.0176844↗
  6. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. Co-author DOI 10.18632/oncotarget.17965↗
  7. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. First author DOI 10.18632/oncotarget.19150↗
  8. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. First author DOI 10.1097/mpa.0000000000000520↗
  9. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.4506↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lixiang Ma · 4 shared papers, 2017–2023 · strength 0.67
  2. Xu Han · 6 shared papers, 2015–2023 · strength 0.58
  3. Hada Buhe · 2 shared papers, 2023 · strength 0.38
  4. Chenyun Song · 2 shared papers, 2023 · strength 0.38
  5. Jichun Gu · 2 shared papers, 2018–2021 · strength 0.26
  6. Ji Li · 2 shared papers, 2018–2021 · strength 0.26
  7. Deliang Fu · 2 shared papers, 2018–2021 · strength 0.26
  8. Wenhui Lou · 3 shared papers, 2015–2021 · strength 0.25
  9. Yuan Fang · 3 shared papers, 2015–2017 · strength 0.19
  10. Wenhui Lou · 2 shared papers, 2017 · strength 0.15
  11. Dansong Wang · 1 shared paper, 2021 · strength 0.14
  12. Xianmei Yang · 1 shared paper, 2017 · strength 0.08
  13. Chenye Shi · 1 shared paper, 2017 · strength 0.07
  14. Junjie Zhao · 1 shared paper, 2017 · strength 0.07
  15. Yefei Rong · 1 shared paper, 2017 · strength 0.07
  16. Tiantao Kuang · 1 shared paper, 2017 · strength 0.07
  17. Anirban Maitra · 1 shared paper, 2015 · strength 0.04
  18. David Arthur Tuveson · 1 shared paper, 2015 · strength 0.04
  19. Long Yu · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.